Mehmet Hakan BİLGİN
Ahi Evran Tıp Dergisi - 2026;10(1):4-6
The GOLD 2025 guideline is introduced as a significant advancement in the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease (COPD). It also aims to harmonize clinical practices globally by providing updated definitions, treatment algorithms, and prevention strategies grounded in current scientific research. The guideline integrates the latest scientific evidence to offer a structured approach for addressing this chronic condition, which remains one of the leading causes of morbidity and mortality worldwide. While the previous versions of the GOLD guideline included a dedicated section on COVID-19 and COPD, this is removed in the GOLD 2025 update. This reflects the transition from pandemic-focused recommendations to long-term chronic disease management priorities. One of the key highlights of the guideline is the refined understanding of COPD pathogenesis. Environmental factors such as cigarette smoke, biomass smoke, and air pollution are shown to play a pivotal role, while genetic predispositions, including alpha-1 antitrypsin deficiency, gain more focus in disease susceptibility. This refinement paves the way for more effective prevention strategies. In addition to these factors, GOLD 2025 introduces dysbiosis as a novel concept in COPD pathogenesis. Dysbiosis, defined as an imbalance in the respiratory tract microbiota, is associated with increased airway inflammation, higher exacerbation risk, and impaired host defense mechanisms. GOLD 2025 also introduces the impact of climate change as a novel environmental determinant of COPD outcomes. Rising global temperatures, worsening air pollution, and extreme events such as heatwaves and wildfires are linked to increased exacerbation frequency, hospitalizations and mortality in COPD patients. Diagnostic advancements, particularly the increased reliance on spirometry, biomarkers, and imaging techniques, are demonstrated to improve the accuracy of disease assessment. GOLD 2025 emphasizes the importance of symptom assessment tools, such as the COPD Assessment Test (CAT) and the modified Medical Research Council (mMRC) dyspnea scale, in evaluating disease severity and guiding therapeutic decisions. Moreover, the integration of high-resolution computed tomography (HRCT) and advanced imaging technologies enhances the ability to detect early structural changes in COPD, offering a more precise evaluation of disease progression. The guideline also underscores the role of early screening and systematic intervention strategies in high-risk but undiagnosed populations, particularly smokers and individuals with significant environmental or occupational exposure. Such proactive approaches are essential to delay disease progression and minimize long-term complications. In treatment, personalized therapy is highlighted as central. The guideline promotes a treatable traits approach, where patient-specific phenotypes and comorbidities are addressed to optimize therapeutic outcomes. New bronchodilator therapies, including agents like ensifentrine and dupilumab, are shown to reduce exacerbations and improve lung function. GOLD 2025 also stresses the importance of inhaler device selection tailored to patient preference, physical ability, and inhalation technique. GOLD 2025 highlighted pulmonary hypertension associated with COPD (PH-COPD) as a distinct treatable trait. Patients with this phenotype often present with severe dyspnea, low diffusing capacity (DLCO), and reduced exercise tolerance. The guideline recommends careful differentiation from pulmonary arterial hypertension and tailored management including optimized bronchodilation, oxygen therapy, and pulmonary rehabilitation to improve functional outcomes. Vaccination is emphasized as a cornerstone in COPD management. GOLD 2025 highlights the necessity of influenza, pneumococcal, and RSV vaccinations to prevent infectious exacerbations, while also focusing on newer technologies such as mRNA vaccines for respiratory pathogens. These vaccination strategies are shown to significantly reduce hospital admissions and complications related to respiratory infections in COPD patients. Pulmonary rehabilitation is identified as a critical component of COPD care, focusing on improving physical capacity, managing comorbidities, and enhancing overall quality of life. Tele-rehabilitation programs are also effective tools for increasing accessibility to rehabilitation services, especially for patients in remote areas or those with mobility limitations. Additionally, the inclusion of mental health support and nutritional counseling within rehabilitation programs further emphasizes the holistic approach advocated by GOLD 2025. Patient education and self-management are identified as integral components of effective COPD management. Educational programs focusing on inhaler techniques, medication adherence, and early recognition of exacerbation symptoms are highlighted as critical for reducing hospitalizations and improving overall outcomes. Furthermore, GOLD 2025 underscores the importance of addressing comorbidities such as cardiovascular diseases, osteoporosis, and depression, which frequently accompany COPD. A multidisciplinary team approach involving pulmonologists, primary care physicians, physiotherapists, and psychologists is recommended to ensure comprehensive care for COPD patients. GOLD 2025 also emphasizes the need for ongoing research and innovation in COPD care. Emerging therapies, including biologics and targeted treatments, are recognized as promising areas for improving disease management in the coming years. In conclusion, GOLD 2025 provides a clear, evidence-based roadmap for COPD management. Its emphasis on personalized treatment, vaccination strategies, pulmonary rehabilitation, and patient education aimed to improve patient outcomes while reducing the global healthcare burden associated with COPD. This guideline serves as a vital tool for clinicians, researchers, and policymakers striving to address the challenges posed by COPD effectively.
